186 related articles for article (PubMed ID: 27340556)
1. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients.
Mushiroda T; Yanai H; Yoshiyama T; Sasaki Y; Okumura M; Ogata H; Tokunaga K
Hum Genome Var; 2016; 3():16014. PubMed ID: 27340556
[TBL] [Abstract][Full Text] [Related]
2. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
3. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
5. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
[TBL] [Abstract][Full Text] [Related]
6. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
8. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
[TBL] [Abstract][Full Text] [Related]
9. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
10. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
[No Abstract] [Full Text] [Related]
11. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
12. Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population.
Yadav D; Kumar R; Dixit RK; Kant S; Verma A; Srivastava K; Singh SK; Singh S
Cureus; 2019 Apr; 11(4):e4425. PubMed ID: 31245212
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
14. Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity.
Yoon JG; Jang DG; Cho SG; Lee C; Noh SH; Seo SK; Yu JW; Chung HW; Han K; Kwon SS; Han DH; Oh J; Jang IJ; Kim SH; Jee YK; Lee H; Park DW; Sohn JW; Yoon HJ; Kim CH; Lee JM; Kim SH; Lee MG
Exp Mol Med; 2024 Mar; 56(3):570-582. PubMed ID: 38424191
[TBL] [Abstract][Full Text] [Related]
15. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
[TBL] [Abstract][Full Text] [Related]
16. Genetic characterization of
Yuliwulandari R; Prayuni K; Razari I; Susilowati RW; Zulhamidah Y; Soedarsono S; Sofro ASM; Tokunaga K
Pharmacogenomics; 2021 Feb; 22(3):157-163. PubMed ID: 33399479
[No Abstract] [Full Text] [Related]
17. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
20. CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.
Perwitasari DA; Irham LM; Darmawan E; Mulyani UA; Atthobari J
Indian J Tuberc; 2016 Jul; 63(3):139-143. PubMed ID: 27865233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
